Cargando…
RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study
To evaluate the efficacy and safety of 2 dosing regimens of ranibizumab 0.5 mg versus verteporfin photodynamic therapy in Asian patients with visual impairment due to myopic choroidal neovascularization. METHODS: Eligible patients (aged ≥18 years) were randomized 2:2:1 to Group I (n = 182; ranibizum...
Autores principales: | Chen, Youxin, Sharma, Tarun, Li, Xiaorong, Song, Yanping, Chang, Qing, Lin, Renxin, Egger, Anna, Foo, Arthur, Gekkieva, Margarita, Lai, Timothy Y. Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Retina
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768610/ https://www.ncbi.nlm.nih.gov/pubmed/30204730 http://dx.doi.org/10.1097/IAE.0000000000002292 |
Ejemplares similares
-
Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK
por: Claxton, Lindsay, et al.
Publicado: (2014) -
VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017) -
Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011) -
Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks
por: Lee, Jun Mok, et al.
Publicado: (2007) -
Photodynamic Therapy with Verteporfin for Corneal Neovascularization
por: Al-Torbak, Abdullah A.
Publicado: (2012)